[Pro7]-Neurokinin B is a synthetic Neurokinin B analog in which the native Val7 residue is replaced by proline. The peptide retains the full 10-residue Neurokinin B backbone and C-terminal amide while introducing a conformationally restrictive residue at position 7.

This analog has been used as a selective NK3 receptor agonist in tachykinin pharmacology, including studies designed to distinguish NK3-mediated responses from NK1- and NK2-receptor signaling.

Product Information

Pro7 Substitution in the Neurokinin B Scaffold

Native Neurokinin B contains Val at position 7. Replacement with Pro introduces a cyclic secondary amino acid that restricts local backbone flexibility and changes the conformational space available to the central portion of the peptide.

Classical tachykinin structure–activity studies found that introduction of imino-acid residues such as Pro at this position can favor NK3 receptor activity. [Pro7]-Neurokinin B subsequently became a useful peptide agonist for experimentally identifying NK3-mediated responses.

Using [Pro7]-Neurokinin B as an NK3 Pharmacology Tool

[Pro7]-Neurokinin B has been used in physiological models where receptor-selective tachykinin agonists are compared side by side. For example, central administration in rats produced dose-dependent pressor responses, supporting its use as an NK3-active pharmacological probe.

We recommend interpreting responses in the context of the species and tissue preparation. Historical tachykinin receptor classifications were often established in isolated tissues, and apparent selectivity can differ from potency measured with recombinant human TACR3.

Research Applications

This peptide can support NK3 receptor pharmacology, Neurokinin B structure–activity studies, receptor subtype characterization, cardiovascular signaling experiments and comparative tachykinin functional assays.

Because the sequence contains two methionine residues, oxidation should be considered in experiments sensitive to peptide integrity. Methionine oxidation can generate detectable mass shifts and may alter the composition of aged or repeatedly handled samples.

Frequently Asked Questions

What is modified in [Pro7]-Neurokinin B?

The native Val residue at position 7 of Neurokinin B is replaced by Pro.

Is [Pro7]-Neurokinin B an NK3 agonist?

Yes. It has been widely used as a selective peptide agonist for NK3 receptor pharmacology.

Why is Pro7 experimentally useful?

Proline restricts local peptide conformation, allowing researchers to investigate how backbone geometry around position 7 contributes to Neurokinin B receptor recognition.

Is the C-terminus amidated?

Yes. The peptide terminates in Met-NH₂.

Research Use Only.